Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $289000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 2.85% to $289000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 44.53% year-over-year, with the annual reading at $1.1 million for FY2025, 44.53% up from the prior year.
  • Depreciation & Amortization (CF) hit $289000.0 in Q4 2025 for Corcept Therapeutics, roughly flat from $289000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.2 million in Q2 2021 to a low of -$1.7 million in Q3 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $265850.0 across 5 years, with a median of $283000.0 in 2024.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 1687.9% in 2021; the steepest drop was 2085.88% in 2021.
  • Year by year, Depreciation & Amortization (CF) stood at $289000.0 in 2021, then surged by 128.37% to $660000.0 in 2022, then tumbled by 67.58% to $214000.0 in 2023, then skyrocketed by 31.31% to $281000.0 in 2024, then grew by 2.85% to $289000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CORT at $289000.0 in Q4 2025, $289000.0 in Q3 2025, and $286000.0 in Q2 2025.